Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,047 mentions
- robotic manipulationmarket829 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology353 mentions
- agentic AItechnology353 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Hypercon
technology2 mentionslast seen Sep 18, 2026
Microparticle technology for hyperconcentration of drugs and biologics.
Relationships 6
- Halozyme Therapeutics, Inc.developsHypercon99% confidence2 sources
- JanssencommercializesHypercon88% confidence1 source
- Eli LillycommercializesHypercon88% confidence1 source
- argenxcommercializesHypercon88% confidence1 source
- Vertex PharmaceuticalscommercializesHypercon88% confidence1 source
- Oruka TherapeuticscommercializesHypercon88% confidence1 source
Relationship
Halozyme Therapeutics, Inc.developsHypercon
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 18, 2026HALOZYME THERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™
- filingSEC EDGARSep 16, 2026HALOZYME THERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™